Armstrong Advisory Group’s Novo Nordisk NVO Stock Holding History

Armstrong Advisory Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.1K	Hold	715	–	–	﹤0.01%	530
2026 Q2	$34.3K	Buy	715 +600	+522%	+$25.8K	﹤0.01%	501
2026 Q1	$4.23K	Hold	115	–	–	﹤0.01%	797
2025 Q4	$5.85K	Sell	115 -93	-45%	-$4.76K	﹤0.01%	756
2025 Q3	$11.5K	Sell	208 -270	-56%	-$15.8K	﹤0.01%	650
2025 Q2	$33K	Buy	478 +118	+33%	+$8.03K	﹤0.01%	460
2025 Q1	$31K	Hold	360	–	–	﹤0.01%	449
2024 Q4	$31K	Sell	360 -81	-18%	-$8.76K	﹤0.01%	449
2024 Q3	$52.5K	Sell	441 -587	-57%	-$78.3K	﹤0.01%	360
2024 Q2	$147K	Buy	+1,028	New	+$136K	0.01%	217

Other funds holding NVO

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Armstrong Advisory Group's NVO Position: Q3 2026 in Review

Armstrong Advisory Group held its Novo Nordisk (NVO) position steady in Q3 2026 at 715 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #530.

Armstrong Advisory Group first reported a position in NVO in Q2 2024 and has held it in 10 quarters since. The position peaked at $147K in Q2 2024. 816 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Armstrong Advisory Group held 715 shares of Novo Nordisk worth $27.1K as of Q3 2026.
Armstrong Advisory Group left its Novo Nordisk share count unchanged in Q3 2026.
Novo Nordisk made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #530 holding.
Armstrong Advisory Group first reported a position in Novo Nordisk in Q2 2024 and has held it in 10 quarters since.
Armstrong Advisory Group's Novo Nordisk position peaked at $147K in Q2 2024.
816 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.